| Literature DB >> 30085086 |
Gerhard Steinbeck1, Moritz F Sinner2,3, Manuel Lutz4, Martina Müller-Nurasyid2,3,4, Stefan Kääb2,3, Holger Reinecke5.
Abstract
Aims: Risks of catheter ablation for atrial fibrillation and flutter assessed in retrospective studies, registries, and controlled trials may underestimate 'real world' conditions. Methods and results: To assess complications in a nationwide approach, we included all cases undergoing catheter ablation for atrial fibrillation and atrial flutter in Germany in 2014, using ICD-10-GM-based German Diagnosis Related Group (G-DRG) codes and the well differentiated German Operation and Procedure Classification (OPS) analysing 33 353 in-hospital cases. For left atrial ablations (19 514 cases), the overall complication rate ranged from a mean of 11.7% to 13.8% depending on type and site of applied energy, including major complications ranging from 3.8% to 7.2%. Whereas overall complication rates were lower for atrial flutter ablations (13 871 cases, 10.5%; P < 0.001), interestingly, major complications occurred more frequently (7.4%; P < 0.001). Particularly, in-hospital death was four-times more common following right than following left atrial ablations (47 vs. 18 cases, 0.34% vs. 0.09%; P < 0.001). Stratified by centre ablation volume, significantly fewer overall complications occurred in centres performing >100 vs. ≤100 left atrial ablations annually (12.7% vs. 16.4%; P < 0.002).Entities:
Mesh:
Year: 2018 PMID: 30085086 PMCID: PMC6269631 DOI: 10.1093/eurheartj/ehy452
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Incidence of procedure related complications, stratified by patient group
| Complications, | Cryoablation | PV isolation | LA ablation | LA + RA ablation | RA ablation |
|---|---|---|---|---|---|
| Group 1 ( | Group 2 ( | Group 3 ( | Group 4 ( | Group 5 ( | |
| In-hospital death* | 8 (3–17) (0.1) | 0 (0–5) (0.0) | 7 (3–16) (0.1) | 3 (0–10) (0.1) | 47 (34–64) (0.3) |
| Stroke* | 27 (18–40) (0.5) | 17 (10–28) (0.5) | 48 (35–65) (0.6) | 15 (8–26) (0.6) | 70 (54–89) (0.5) |
| Pneumonia* | 30 (20–44) (0.5) | 23 (14–36) (0.7) | 88 (71–109) (1.1) | 25 (16–38) (1.0) | 282 (250–317) (2.0) |
| Phrenic nerve injury* | 21 (13–33) (0.4) | n.a. | n.a. | n.a. | 8 (3–17) (0.1) |
| Cardiac arrest* | 13 (7–23) (0.2) | 3 (0–10) (0.1) | 17 (10–28) (0.2) | 7 (3–16) (0.3) | 49 (36–66) (0.4) |
| AV Block III°* | 11 (5–21) (0.2) | 9 (4–18) (0.3) | 29 (19–43) (0.3) | 8 (3–17) (0.3) | 223 (195–255) (1.6) |
| Pericardial effusion | 167 (143–195) (3.0) | 100 (81–122) (3.2) | 305 (272–341) (3.7) | 98 (80–120) (4.1) | 237 (208–270) (1.7) |
| Pericardial drainage* | 42 (29–55) (0.7) | 26 (16–36) (0.8) | 113 (92–134) (1.4) | 20 (11–29) (0.8) | 47 (34–60) (0.3) |
| Access site complications | 411 (373–452) (7.3) | 219 (192–250) (6.9) | 655 (607–706) (7.9) | 149 (127–175) (6.2) | 536 (492–583) (3.9) |
| Vascular intervention /surgery* | 15 (7–23) (0.3) | 15 (7–23) (0.5) | 97 (78–116) (1.2) | 12 (5–19) (0.5) | 80 (62–98) (0.6) |
| Transfusion* | 48 (34–62) (0.9) | 40 (28–52) (1.3) | 203 (175–231) (2.4) | 35 (23–47) (1.5) | 222 (193–251) (1.6) |
| Total, overall | 688 (637–739) (12.3) | 371 (333–409) (11.7) | 1149 (1083–1215) (13.8) | 305 (271–339) (12.7) | 1452 (1377–1527) (10.5) |
| Total, major | 215 (186–244) (3.8) | 133 (110–156) (4.2) | 602 (554–650) (7.2) | 125 (103–147) (5.2) | 1028 (965–1091) (7.4) |
Major complications are marked by an asterisk (*). Complications are presented as incident cases (percentage), stratified by pre-specified patient groups. Access site complications consist of bleeding, haematoma, shock, infection, and vascular complications. Detailed group definitions are provided in the methods section.
LA, left atrium; n.a., not assessed (indicates table cell with too few observations for display due to data protection policies); RA, right atrium.
Incidence of procedure related complications of left vs. right atrial ablations, stratified by centre ablation volume
| Complications, | Isolated pulmonary vein isolation and/or left atrial ablation | Isolated right atrial ablation | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Centre ablation volume | Centre ablation volume | |||||||||
| ≤25 ( | 26–50 ( | 51–100 ( | 101–300 ( | >300 ( | ≤25 ( | 26–50 ( | 51–100 ( | 101–300 ( | >300 ( | |
| In-hospital death* | 0 (0–5) (0) | 0 (0–5) (0) | 0 (0–5) (0) | 8 (3–17) (0.1) | 8 (3–17) (0.1) | 0 (0–5) (0) | n.a. | n.a. | 20 (12–32) (0.4) | 20 (12–32) (0.3) |
| Stroke* | 0 (0–5) (0) | n.a. | n.a. | 29 (19–43) (0.5) | 60 (46–78) (0.6) | n.a. | n.a. | 7 (3–16) (0.6) | 33 (23–47) (0.7) | 26 (17–39) (0.4) |
| Pneumonia* | n.a. | 3 (0–10) (1.2) | 11 (5–21) (1.7) | 62 (47–80) (1.1) | 65 (50–84) (0.6) | 7 (3–15) (2.7) | 10 (5–19) (1.5) | 28 (19–41) (2.4) | 141 (120–165) (2.8) | 96 (78–118) (1.4) |
| Phrenic nerve injury* | 0 (0–5) (0) | 0 (0–5) (0) | n.a. | 9 (4–18) (0.2) | 14 (7–25) (0.1) | 0 (0–5) (0) | 0 (0–5) (0) | n.a. | n.a. | 6 (2–14) (0.1) |
| Cardiac arrest* | 0 (0–5) (0) | n.a. | 3 (0–10) (0.5) | 16 (9–27) (0.3) | 13 (7–23) (0.1) | 0 (0–5) (0) | n.a. | n.a. | 21 (13–33) (0.4) | 25 (16–38) (0.4) |
| AV block III°* | 0 (0–5) (0) | 0 (0–5) (0) | n.a. | 18 (11–30) (0.3) | 31 (21–45) (0.3) | 4 (1–11) (1.5) | 9 (4–18) (1.3) | 13 (7–23) (1.1) | 87 (70–107) (1.7) | 110 (90–133) (1.6) |
| Pericardial effusion | n.a. | 7 (3–15) (2.7) | 18 (11–29) (2.8) | 184 (159–213) (3.3) | 370 (334–410) (3.4) | 5 (1–13) (1.9) | 8 (3–17) (1.2) | 13 (7–23) (1.1) | 101 (83–122) (2.0) | 110 (90–133) (1.6) |
| Pericardial drainage* | 0 (0–5) (0) | n.a. | 6 (1–11) (0.9) | 67 (51–83) (1.2) | 110 (89–131) (1.0) | 0 (0–5) (0) | n.a. | n.a. | 21 (12–30) (0.4) | 24 (14–34) (0.4) |
| Access site complications | 6 (2–12) (18.2) | 21 (13–32) (8.1) | 75 (60–93) (11.7) | 434 (395–476) (7.7) | 762 (710–817) (7.1) | 10 (5–19) (3.8) | 27 (18–40) (4.0) | 46 (34–62) (4.0) | 183 (159–209) (3.7) | 270 (239–304) (4.0) |
| Vascular intervention/surgery* | 0 (0–5) (0) | 5 (1–9) (1.9) | n.a. | 69 (53–85) (1.2) | 53 (39–67) (0.5) | n.a. | n.a. | 8 (2–14) (0.7) | 29 (18–40) (0.6) | 34 (23–45) (0.5) |
| Transfusion* | n.a. | 4 (0–8) (1.6) | 10 (4–16) (1.6) | 127 (105–149) (2.3) | 150 (126–174) (1.4) | n.a. | n.a. | 24 (14–34) (2.1) | 81 (63–99) (1.6) | 104 (84–124) (1.5) |
| Total, overall | 6 (2–12) (18.2) | 31 (20–42) (13.2) | 108 (88–128) (17.4) | 760 (706–814) (14.1) | 1323 (1252–1394) (12.8) | 26 (16–36) (10.0) | 54 (40–68) (8.1) | 107 (87–127) (11.2) | 586 (539–633) (13.2) | 663 (613–713) (10.7) |
| Total, major | 0 (0–5) (0) | 12 (5–19) (5.8) | 30 (19–91) (5.5) | 405 (366–444) (7.8) | 504 (460–548) (5.2) | 11 (4–18) (4.2) | 27 (17–37) (4.0) | 80 (62–98) (8.9) | 433 (392–474) (10.1) | 445 (404–486) (7.5) |
Major complications are marked by an asterisk (*). Complications are presented as incidence (percentage), stratified by centre ablation volume and by any pulmonary vein isolation and/or left atrial ablation or isolated right atrial ablation. Centre ablation volume was categorized by centres performing ≤25, 26–50, 51–100, 101–300, or >300 of the respective procedures.
For Table , Group 4 (additional right atrial ablation) is eliminated from the analysis on the left of the table, but the sum (17 349 procedures) is more than the sum of Groups 1–3 (17 111 procedures), as in 238 cases both cryo-energy and RF energy were applied, which are not represented in Table .
n.a., not assessed (indicates table cell with too few observations for display due to data protection policies).
Aggregate patient characteristics
| Cryoablation (Group 1) ( | PV isolation (Group 2) ( | LA ablation (Group 3) ( | LA + RA ablation (Group 4) ( | Any left atrial ablation procedure (Groups 1–4) ( | Isolated right atrial ablation procedure (Group 5) ( | ||
|---|---|---|---|---|---|---|---|
| Age (years), mean ± SD | 62.9 ± 10.7 | 62.7 ± 10.6 | 63.7 ± 10.8 | 63.8 ± 10.9 | 63.3 ± 10.8 | 67.2 ± 11.9 | <0.001 |
| ≤50 years, | 741 (13.2) | 427 (13.5) | 997 (12.0) | 274 (11.4) | 2439 (12.5) | 1210 (8.7) | <0.001 |
| 51–60 years, | 1382 (24.6) | 816 (25.8) | 1959 (23.5) | 553 (23.0) | 4710 (24.1) | 2298 (16.6) | <0.001 |
| 61–70 years, | 1906 (34.0) | 1011 (31.9) | 2686 (32.2) | 773 (32.2) | 6376 (32.7) | 3870 (27.9) | <0.001 |
| 71–80 years, | 1497 (26.7) | 873 (27.6) | 2540 (30.5) | 760 (31.6) | 5670 (29.1) | 5226 (37.7) | <0.001 |
| >80 years, | 82 (1.5) | 40 (1.3) | 154 (1.8) | 43 (1.8) | 319 (1.6) | 1267 (9.1) | <0.001 |
| Males, | 3270 (58.3) | 1941 (61.3) | 5069 (60.8) | 1483 (61.7) | 11769 (60.3) | 9964 (71.8) | <0.001 |
| Paroxysmal atrial fibrillation, | 3893 (69.4) | 1907 (60.2) | 4428 (53.1) | 1048 (43.6) | 11276 (57.8) | 3850 (27.8) | <0.001 |
| Persistent atrial fibrillation, | 1755 (31.3) | 1226 (38.7) | 3508 (42.1) | 1133 (47.1) | 7622 (39.1) | 1602 (11.5) | <0.001 |
| Permanent atrial fibrillation, | 96 (1.7) | 37 (1.2) | 220 (2.6) | 36 (1.5) | 389 (2.0) | 314 (2.3) | 0.10 |
| Atrial flutter, | 312 (5.6) | 324 (10.2) | 1517 (18.2) | 1200 (49.9) | 3353 (17.2) | 12333 (88.9) | <0.001 |
| Hypertension, | 3484 (62.1) | 2062 (65.1) | 5230 (62.7) | 1461 (60.8) | 12238 (62.7) | 8894 (64.1) | 0.009 |
| Chronic obstructive pulmonary disease, | 152 (2.7) | 94 (3.0) | 279 (3.3) | 53 (2.2) | 578 (3.0) | 990 (7.1) | <0.001 |
| Pulmonary hypertension, | 105 (1.9) | 91 (2.9) | 252 (3.0) | 74 (3.1) | 522 (2.7) | 517 (3.7) | <0.001 |
| Obstructive sleep apnoea, | 184 (3.3) | 111 (3.5) | 285 (3.4) | 78 (3.2) | 658 (3.4) | 496 (3.6) | 0.32 |
| Hyperthyroidism, | 113 (2.0) | 93 (2.9) | 219 (2.6) | 40 (1.7) | 465 (2.4) | 302 (2.2) | 0.22 |
| Diabetes mellitus, | 562 (10.0) | 348 (11.0) | 973 (11.7) | 259 (10.8) | 2142 (11.0) | 2754 (19.9) | <0.001 |
| Chronic kidney disease, | 323 (5.8) | 174 (5.5) | 837 (10.0) | 193 (8.0) | 1527 (7.8) | 2066 (14.9) | <0.001 |
| Coronary artery disease, | 1108 (19.8) | 666 (21.0) | 182 (2.2) | 446 (18.6) | 4041 (20.7) | 4452 (32.1) | <0.001 |
| Dilative cardiomyopathy, | 146 (2.6) | 148 (4.7) | 402 (4.8) | 132 (5.5) | 828 (4.2) | 829 (6.0) | <0.001 |
| Heart failure, | 642 (11.4) | 395 (12.5) | 1418 (17) | 455 (18.9) | 2910 (14.9) | 3470 (25.0) | <0.001 |
| Aortic stenosis, | 88 (1.6) | 82 (2.6) | 177 (2.1) | 51 (2.1) | 398 (2.0) | 440 (3.2) | <0.001 |
| Mitral valve disease, | 313 (5.6) | 172 (5.4) | 549 (6.6) | 142 (5.9) | 1176 (6.0) | 936 (6.7) | 0.008 |
| Peripheral artery disease, | 55 (1.0) | 43 (1.4) | 82 (1.0) | 20 (0.8) | 200 (1.0) | 408 (2.9) | <0.001 |
| Duration of hospital stay (days), mean ± SD | 4.2 ± 3.7 | 4.1 ± 3.7 | 4.7 ± 4.4 | 4.6 ± 4.3 | 4.4 ± 4.1 | 5.1 ± 6.7 | <0.001 |
Statistical comparisons are calculated for two columns on the right-hand side. Among them, the left column includes any left atrial ablation procedure using any source of energy, the right column includes isolated right atrial ablation procedures using any source of energy. Comparisons using Fisher’s exact test or Student’s t-test as appropriate.
Aggregate characteristics of patients with and without in-hospital death, pneumonia, cardiac arrest, and AV block III° following isolated right atrial ablation
| Isolated right atrial ablation procedure | Isolated right atrial ablation procedure | Isolated right atrial ablation procedure | Isolated right atrial ablation procedure | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| With in-hospital death | Without in-hospital death | With pneumonia | Without pneumonia | With cardiac arrest | Without cardiac arrest | With AV block III° | Without AV block III° | |||||
| Age (years), mean ± SD | 71.7 ± 9.6 | 67.3 ± 11.9 | 0.011 | 71.3 ± 9.6 | 67.2 ± 11.9 | <0.001 | 69.7 ± 9.9 | 67.3 ± 11.9 | 0.16 | 71.4 ± 12.1 | 67.2 ± 11.8 | <0.001 |
| ≤50 years, | 0 (0.0) | 1210 (8.8) | 0.032 | 7 (2.5) | 1203 (8.9) | <0.001 | n.a. | 1209 (8.7) | n.a. | 15 (6.7) | 1195 (8.8) | 0.34 |
| 51–60 years, | 4 (8.5) | 2294 (16.6) | 0.17 | 30 (10.6) | 2268 (16.7) | 0.006 | 5 (10.2) | 2293 (16.6) | 0.33 | 17 (7.6) | 2281 (16.7) | <0.001 |
| 61–70 years, | 17 (36.2) | 3853 (27.9) | 0.25 | 76 (27.0) | 3794 (27.9) | 0.79 | 17 (34.7) | 3853 (27.9) | 0.34 | 45 (20.2) | 3825 (28.0) | 0.01 |
| 71–80 years, | 16 (34.0) | 5210 (37.7) | 0.65 | 128 (45.4) | 5098 (37.5) | 0.008 | 19 (38.8) | 5207 (37.7) | 0.88 | 100 (44.8) | 5126 (37.6) | 0.031 |
| >80 years, | 10 (21.3) | 1257 (9.1) | 0.009 | 41 (14.5) | 1226 (9.0) | 0.003 | 6 (12.2) | 1261 (9.1) | 0.45 | 46 (20.6) | 1221 (8.9) | <0.001 |
| Males, | 36 (76.6) | 9828 (71.1) | 0.52 | 212 (75.2) | 9652 (71.0) | 0.14 | 36 (73.5) | 9828 (71.1) | 0.88 | 159 (71.3) | 9705 (71.1) | 1.00 |
| Paroxysmal atrial fibrillation, | 16 (34.0) | 3834 (27.7) | 0.33 | 97 (34.4) | 3753 (27.6) | 0.013 | 19 (38.8) | 3831 (27.7) | 0.11 | 59 (26.5) | 3791 (27.8) | 0.71 |
| Persistent atrial fibrillation, | 3 (6.4) | 1599 (11.6) | 0.36 | 51 (18.1) | 1551 (11.4) | 0.001 | 12 (24.5) | 1590 (11.5) | 0.011 | 34 (15.2) | 1568 (11.5) | 0.09 |
| Permanent atrial fibrillation, | 7 (14.9) | 307 (2.2) | <0.001 | 28 (9.9) | 286 (2.1) | <0.001 | 4 (8.2) | 310 (2.2) | 0.025 | 14 (6.3) | 300 (2.2) | 0.001 |
| Atrial flutter, | 36 (76.6) | 12 297 (89.0) | 0.016 | 231 (81.9) | 12 102 (89.1) | <0.001 | 36 (73.5) | 12 297 (89) | 0.002 | 181 (81.2) | 12 152 (89.0) | 0.001 |
| Hypertension, | 27 (57.4) | 8867 (64.1) | 0.36 | 184 (65.2) | 8710 (64.1) | 0.71 | 35 (71.4) | 8859 (64.1) | 0.37 | 159 (71.3) | 8735 (64.0) | 0.024 |
| Chronic obstructive pulmonary disease, | 10 (21.3) | 980 (7.1) | 0.001 | 66 (23.4) | 924 (6.8) | <0.001 | 9 (18.4) | 981 (7.1) | 0.007 | 19 (8.5) | 971 (7.1) | 0.43 |
| Pulmonary hypertension, | 5 (10.6) | 512 (3.7) | 0.03 | 33 (11.7) | 484 (3.6) | <0.001 | 6 (12.2) | 511 (3.7) | 0.009 | 18 (8.1) | 499 (3.7) | 0.002 |
| Obstructive sleep apnoea, | n.a. | 495 (3.6) | n.a. | 18 (6.4) | 478 (3.5) | 0.021 | 3 (6.1) | 493 (3.6) | 0.26 | 20 (9.0) | 476 (3.5) | <0.001 |
| Hyperthyroidism, | 3 (6.4) | 299 (2.2) | 0.08 | 11 (3.9) | 291 (2.1) | 0.059 | n.a. | 301 (2.2) | n.a. | 5 (2.2) | 297 (2.2) | 0.82 |
| Diabetes mellitus, | 21 (44.7) | 2733 (19.8) | <0.001 | 81 (28.7) | 2673 (19.7) | <0.001 | 20 (40.8) | 2734 (19.8) | 0.001 | 57 (25.6) | 2697 (19.8) | 0.034 |
| Chronic kidney disease, | 23 (48.9) | 2043 (14.8) | <0.001 | 109 (38.7) | 1957 (14.4) | <0.001 | 21 (42.9) | 2045 (14.8) | <0.001 | 59 (26.5) | 2007 (14.7) | <0.001 |
| Coronary artery disease, | 27 (57.4) | 4425 (32.0) | <0.001 | 145 (51.4) | 4307 (31.7) | <0.001 | 33 (67.3) | 4419 (32) | <0.001 | 99 (44.4) | 4353 (31.9) | <0.001 |
| Dilative cardiomyopathy, | 5 (10.6) | 824 (6.0) | 0.20 | 36 (12.8) | 793 (5.8) | <0.001 | 5 (10.2) | 824 (6.0) | 0.22 | 26 (11.7) | 803 (5.9) | 0.001 |
| Heart failure, | 31 (66.0) | 3439 (24.9) | <0.001 | 182 (64.5) | 3288 (24.2) | <0.001 | 33 (67.3) | 3437 (24.9) | <0.001 | 87 (39.0) | 3383 (24.8) | <0.001 |
| Aortic stenosis, | 3 (6.4) | 437 (3.2) | 0.19 | 19 (6.7) | 421 (3.1) | 0.003 | 3 (6.1) | 437 (3.2) | 0.20 | 13 (5.8) | 427 (3.1) | 0.032 |
| Mitral valve disease, | 8 (17.0) | 928 (6.7) | 0.012 | 39 (13.8) | 897 (6.6) | <0.001 | 12 (24.5) | 924 (6.7) | <0.001 | 17 (7.6) | 919 (6.7) | 0.59 |
| Peripheral artery disease, | 6 (12.8) | 402 (2.9) | 0.002 | 22 (7.8) | 386 (2.8) | <0.001 | 10 (20.4) | 398 (2.9) | <0.001 | 10 (4.5) | 398 (2.9) | 0.16 |
| Duration of hospital stay (days), mean ± SD | 26.4 ± 19.1 | 5.1 ± 5.8 | <0.001 | 21.7 ± 17.7 | 4.8 ± 5.6 | <0.001 | 29.5 ± 30.9 | 5.1 ± 5.8 | <0.001 | 9.6 ± 12.8 | 5.1 ± 5.8 | <0.001 |
Statistical comparisons are calculated for the respective subgroups of patients with or without the complication of interest. Comparisons using Fisher’s exact test or Student’s t-test as appropriate.
n.a., not assessed (indicates table cell with too few observations for display due to data protection policies).